Department of Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.
Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu, 611731, China.
Biomark Med. 2024;18(10-12):545-553. doi: 10.1080/17520363.2024.2347190. Epub 2024 Aug 13.
To investigate the association between plasma AAT level and glaucoma. 163 glaucoma patients and 111 healthy controls were recruited. The plasma AAT levels were measured by ELISA. Plasma AAT level was significantly higher in glaucoma patients than those in healthy controls ( < 0.001). Patients with higher plasma AAT level exhibited severer disease stage (early vs. severe: < 0.05; H-P-A; early vs. severe: < 0.05; early vs. end-stage: < 0.01; AGIS). ROC curves yielded that AAT can distinguish patients with early glaucoma from those with advanced glaucoma (early vs. severe: AUC: 0.616; H-P-A; early vs. severe: AUC: 0.763; early vs. end-stage: AUC: 0.660; AGIS). Plasma AAT is a useful biomarker for the identification of glaucoma severity.
研究血浆 AAT 水平与青光眼的关系。方法：招募 163 例青光眼患者和 111 例健康对照者。采用 ELISA 法检测血浆 AAT 水平。结果：青光眼患者的血浆 AAT 水平显著高于健康对照组（<0.001）。血浆 AAT 水平较高的患者疾病分期更严重（早期与严重：<0.05；H-P-A；早期与严重：<0.05；早期与终末期：<0.01；AGIS）。ROC 曲线分析表明，AAT 可区分早期青光眼和晚期青光眼患者（早期与严重：AUC：0.616；H-P-A；早期与严重：AUC：0.763；早期与终末期：AUC：0.660；AGIS）。结论：血浆 AAT 是识别青光眼严重程度的有用生物标志物。
